Information on autochthonous vectorial transmission of dengue in mainland EU/EEA, including location, period, number of cases, virus serotype and mode of transmission.
Immunisation is the only effective method of prevention. Mumps vaccine is given in the form of the combined trivalent measles-mumps-rubella (MMR) vaccine in all European countries with a first dose at or before 18 months of age. The timing of the second dose varies across countries.
On 14-15 January 2015 an ECDC consultation gathered public health experts, entomologists and epidemiologists from Europe, as well as experts from WHO, CDC and PacNet, to review the EU preparedness to dengue and chikungunya importation and onwards transmission and produce a roadmap towards improved EU preparedness.
ECDC promotes the performance of external quality assessment (EQA) schemes, in which laboratories are sent simulated clinical specimens or bacterial isolates for testing by routine or reference laboratory methods. EQA schemes, or laboratory proficiency testing, provide information about the accuracy of different characterisation and typing methods as well as antimicrobial susceptibility testing (AST) and the sensitivity of the methods in place to detect a certain pathogen or novel resistance patterns.